Austin Health

Title
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.
Publication Date
2019-08
Author(s)
Sasadeusz, Joe
Grigg, Andrew P
Hughes, Peter D
Lee Lim, Seng
Lucas, Michaela
McColl, Geoff
McLachlan, Sue Anne
Peters, Marion G
Shackel, Nicholas
Slavin, Monica
Sundararajan, Vijaya
Thompson, Alexander
Doyle, Joseph
Rickard, James
De Cruz, Peter
Gish, Robert G
Visvanathan, Kumar
Subject
Anti-CD20
Direct-acting antivirals
Hepatitis B
Inflammatory bowel diseases
Reactivation
Rheumatoid arthritis
Type of document
Journal Article
DOI
10.1016/j.cld.2019.04.012
Abstract
Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.
Link
Citation
Clinics in liver disease 2019; 23(3): 521-534
Jornal Title
Clinics in liver disease

Files:

NameSizeformatDescriptionLink